Eric’s practice is focused on complex litigation with an emphasis on pharmaceutical and medical device product liability claims. Eric has experience defending significant lawsuits in multidistrict litigation as well as individual cases pending in state and federal courts across the country.

Eric has served as counsel for clients in cases involving numerous prescription drugs, including prescription sleep aids and acne medication. He has also represented a large medical device manufacturer in a mass tort involving a 510(k) medical device. That litigation effectively ended after a three-day joint hearing culminated in the state and federal courts excluding all of the plaintiffs’ causation experts.

Eric has participated in every stage of litigation from initial case work-up and discovery through trial. He has significant experience preparing company witnesses and experts and mounting successful Daubert challenges to opposing experts.

Eric has utilized his scientific background throughout his career to the benefit of his clients. He has extensive experience developing strategies to address complex scientific issues.

Eric’s trial experience includes serving key roles on multiple trial teams that have achieved defense verdicts and favorable outcomes for his clients. He has also tried an Eighth Amendment pro bono case to verdict. During his career, Eric has likewise had success disposing of cases before trial through discovery and motion practice.

In graduate school, Eric studied cancer and cellular biology at one of the most renowned cancer institutions in the world. He co-authored papers looking at the role of cell death in the progression of oral cancer. He also has experience working in vaccine development, drug development and biotechnology. While in law school, he was a member of the UMKC Law Review, the Moot Court National Team and Order of the Barristers.


Eric Swan & Jon Strongman, The Abuse of Biological Plausibility as a Factor, For the Defense, September 2013, at 78. 

Mandal M, Younes M, Swan EA, Jasser SA, Doan D, Yigitbasi O, McMurphy A, Ludwick J, El-Naggar AK, Bucana C, Mills GB, Myers JN, The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck, Oral Oncol. 42(4):430-9; April 2006.

Swan EA, Jasser SA, Holsinger FC, Doan D, Bucana C, Myers JN, Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer, Oral Oncol. 39(7):648-55; October 2003.

Holsinger FC, Doan DD, Jasser SA, Swan EA, Greenberg JS, Schiff BA, Bekele BN, Younes MN, Bucana CD, Fidler IJ, Myers JN, Epidermal growth factor receptor blockade potentiates apoptosis mediated by paclitaxel and leads to prolonged survival in a murine model of oral cancer, Clin Cancer Res. 9(8):3183-89; August 2003.

Castilleja A, Ward NE, O'Brian CA, Swearingen B 2nd, Swan E, Gillogy MA, Murray JL, Kudelka AP, Gershenson DM, Ioannides CG, Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity, Mol Cell Biochem. 217(1-2):21-33; January 2001.